Tirzepatide

Amino Acid Sequence:

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Chemical Formula:

C₂₂₅H₃₄₈N₄₈O₆₈

CAS Registry Number:

2023788-19-2

• Type 2 diabetes & glycemic control

• Obesity & severe obesity

• Cardiometabolic disease risk reduction

• NAFLD/NASH & hepatic metabolic dysfunction

• Metabolic syndrome & insulin resistance

• Appetite regulation & energy‑balance research

• Weight‑maintenance strategies post‑loss

Dual Incretin Receptor Activation

• GLP‑1 receptor: appetite suppression, delayed gastric emptying, improved glycemic control

• GIP receptor: enhanced insulin secretion, metabolic synergy with GLP‑1, improved energy balance

Metabolic & Weight‑Loss Effects

• Reduces appetite and caloric intake

• Enhances fat oxidation and metabolic flexibility

• Improves insulin sensitivity and glucose homeostasis

Cardiometabolic Influence

• Improves lipid profiles

• Reduces inflammatory markers

• Supports cardiovascular and hepatic metabolic health

Tirzepatide is FDA‑approved for type 2 diabetes and is undergoing expanded regulatory review for obesity and related metabolic indications. While its weight‑loss efficacy has generated global interest, all non‑diabetes applications remain investigational pending regulatory decisions. Its strong clinical data, dual‑agonist mechanism, and extensive real‑world interest continue to position Tirzepatide as a leading therapeutic in metabolic‑health research.

1. Santulli G. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. N Engl J Med. 2022 Feb 17;386(7)

2. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023 Nov;29(11):2909-2918

3. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024 Sep 1;184(9):1056-1064

4. Hannon TS, Chao LC, Barrientos-Pérez M, Pamidipati KC, Landó LF, Lee CJ, Patel H, Bergman BK. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2025 Oct 4;406(10511):1484-1496

5. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216

CURRENT BATCH LOT NUMBER: T2002026-05-13

CERTIFICATE OF ANALYSIS – TGMPURE Tirzepatide 20 MG (T202026-05-13)